By Ekta Batra, CNBC-TV18
Ranbaxy Laboratories is to announce its Q4CY11. According to CNBC-TV18 estimates, the company's Q4CY11 revenues are seen up 48% to Rs 3156 crore versus Rs 2129 crore. Its EBITDA at Rs 832 crore versus Rs 230 crore. Its OPM 26.4% versus 10.8%. The company's PAT is seen at Rs 575 crore versus loss of Rs 97.5 crore.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!